Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy

References

• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019–5032.
   PubMed Web of Science ®Google Scholar
• Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008;111:3941–3967.
   PubMed Web of Science ®Google Scholar
• Mateo G, Montalbán MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008;26:2737–2744.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100:3095–3100.
   PubMed Web of Science ®Google Scholar
• Nolan GP. Flow cytometry in the post fluorescence era. Best Pract Res Clin Haematol 2011;24:505–508.
   PubMed Web of Science ®Google Scholar
• Paiva B, Almeida J, Pérez-Andrés M, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 2010;78:239–252.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:1908–1975.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Orfao A, Beksac M, et al. European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93:431–438.
   PubMed Web of Science ®Google Scholar
• Visvader JE. Cells of origin in cancer. Nature 2011;469:314–322.
   PubMed Web of Science ®Google Scholar
• Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481:306–313.
   PubMed Web of Science ®Google Scholar
• Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175–187.
   PubMed Web of Science ®Google Scholar
• Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012;12:767–775.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Kuehl M, Lodahl M, et al. Possible roles for activating RAS mutations in MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005;105:317–323.
   PubMed Web of Science ®Google Scholar
• Killmann SA. Acute leukaemia: development, remission/relapse pattern, relationship between normal and leukaemic haemopoiesis, and the “sleeper-to-feeder” stem cell hypothesis. Baillieres Clin Haematol 1991;4:577–598.
   PubMedGoogle Scholar
• Johnsen HE, Kjeldsen MK, Urup T, et al. Cancer stem cells and the cellular hierarchy in haematological malignancies. Eur J Cancer 2009;45(Suppl. 1):194–201.
   PubMedGoogle Scholar
• Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol 2008;26:2795–2799.
   PubMed Web of Science ®Google Scholar
• Martinez-Climent JA, Fontan L, Gascoyne RD, et al. Lymphoma stem cells: enough evidence to support their existence?Haematologica 2010;95:293–302.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Renné C, Rosenquist R, et al. Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin's and non-Hodgkin's lymphomas. Leukemia 2005;19: 1452–1458.
   PubMed Web of Science ®Google Scholar
• Matthias P, Rolink AG. Transcriptional networks in developing and mature B-cells. Nat Rev Immunol 2005;5:497–508.
   PubMed Web of Science ®Google Scholar
• Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008;8:22–33.
   PubMed Web of Science ®Google Scholar
• McHeyzer-Williams M, Okitsu S, Wang N, et al. Molecular programming of B-cell memory. Nat Rev Immunol 2011;12:24–34.
   PubMed Web of Science ®Google Scholar
• Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity 2007;27:190–202.
   PubMed Web of Science ®Google Scholar
• Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102:553–563.
   PubMed Web of Science ®Google Scholar
• Perez-Andres M, Paiva B, Nieto WG, et al. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom 2010;78(Suppl. 1):S47–S60.
   PubMed Web of Science ®Google Scholar
• Kjeldsen MK, Perez-Andres M, Schmitz A, et al. Multiparametric flow cytometry for identification and fluorescence activated cell sorting of five distinct B-cell subpopulations in normal tonsil tissue. Am J Clin Pathol 2011;136:960–969.
   PubMed Web of Science ®Google Scholar
• Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 2008;205:2251–2268.
   PubMed Web of Science ®Google Scholar
• Eckerle S, Brune V, Döring C, et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 2009;23:2129–2138.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Döring C, Brune V, et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood 2012;120:4609–4620.
   PubMed Web of Science ®Google Scholar
• Bergkvist KS, Nyegaard M, Bøgsted M, et al. A modified method for microarray gene expression profiling of minor B-cell subpopulations in man. Submitted 2013.
   Google Scholar
• Pajares MJ, Ezponda T, Catena R, et al. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007;8:349–357.
   PubMed Web of Science ®Google Scholar
• Shmueli G. To explain or to predict?. Stat Sci 2010;25:289–310.
   Web of Science ®Google Scholar
• Speed T. Statistical analysis of gene expression microarray data. Boca Raton, FL: Chapman & Hall/CRC; 2003.
   Google Scholar
• Knudsen S. A biologist's guide to analysis of DNA microarray data. New York: John Wiley & Sons; 2002.
   Google Scholar
• Gentleman R, Carey V, Huber W, et al., editors. Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer; 2005.
   Google Scholar
• Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3: Article3.
   PubMedGoogle Scholar
• Benjamini Y, Hochberg Y, Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289–300.
   Google Scholar
• Tibshirani R, Hastie T, Narasimhan B, et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002;99:6567–6572.
   PubMed Web of Science ®Google Scholar
• Fan J, Fan Y. High dimensional classification using features annealed independence rules. Ann Stat 2008;36:2605–2637.
   PubMed Web of Science ®Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010;33:1–22.
   PubMed Web of Science ®Google Scholar
• Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
   PubMed Web of Science ®Google Scholar
• The R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2010.
   Google Scholar
• Bergsagel PL, Chesi M, Nardini E, et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996;93:13931–13936.
   PubMed Web of Science ®Google Scholar
• Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417–1429.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Hummel M, Bentink S, Berger H, et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419–2430.
   Google Scholar
• Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43:830–837.
   PubMed Web of Science ®Google Scholar
• Lenz G, Nagel I, Siebert R, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B-cell-like diffuse large B-cell lymphoma. J Exp Med 2007;204: 633–643.
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004;21:81–93.
   PubMed Web of Science ®Google Scholar
• Seifert M, Kuppers R. Molecular footprints of a germinal center derivation of human IgM+(IgD+)CD27 + B-cells and the dynamics of memory B-cell generation. J Exp Med 2009;206: 2659–2669.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Guglielmino R, Houldsworth J, et al. Expression of the AID protein in normal and neoplastic B-cells. Blood 2004; 104:3318–3325.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008;105:13520–13525.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Alizadeh AA, Eisen MB, et al. Ongoing immunoglobulin somatic mutation in germinal center B-cell-like but not in activated B-cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 2000;97:10209–10213.
   PubMed Web of Science ®Google Scholar
• Küppers R, Klein U, Hansmann ML, et al. Cellular origin of human B-cell lymphomas. N Engl J Med 1999;341:1520–1529.
   PubMed Web of Science ®Google Scholar
• Bergkvist K, Bøgsted M, Schmitz A, et al. Characterization of memory B-cells from thymus and its impact for DLBCL classification. In preparation 2013.
   Google Scholar
• Kyle AR, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860–1873.
   PubMed Web of Science ®Google Scholar
• Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3–21.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM, Zhan F, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296–303.
   PubMed Web of Science ®Google Scholar
• Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745–1757.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl M. Chromosome translocation in multiple myeloma. Oncogene 2001;20:5611–5622.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Chesi M, Nardini E, et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996;93:13931–13936.
   PubMed Web of Science ®Google Scholar
• Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16:260–264.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Theilgaard-Mönch K, Hudlebusch HR, et al. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities. Br J Haematol 2003;123: 253–262.
   PubMed Web of Science ®Google Scholar
• Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003;102:4504–4511.
   PubMed Web of Science ®Google Scholar
• Fenton JA, Pratt G, Rawstron AC, et al. Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism. Oncogene 2003;22:1103–1113.
   PubMed Web of Science ®Google Scholar
• Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471:467–472.
   PubMed Web of Science ®Google Scholar
• Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012;120:1060–1066.
   PubMed Web of Science ®Google Scholar
• Leich E, Weißbach S, Klein HU, et al. Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules. Blood Cancer J 2013;3:e102.
   PubMed Web of Science ®Google Scholar
• Vicente-Dueñas C, Romero-Camarero I, González-Herrero I, et al. A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J 2012;31:3704–3717.
   Google Scholar
• Rasmussen T, Lodahl M, Hancke S, et al. In multiple myeloma clonotypic CD38- /CD19+ / CD27 + memory B-cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma 2004;45:1413–1417.
   PubMed Web of Science ®Google Scholar
• Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190–197.
   PubMed Web of Science ®Google Scholar
• Paíno T, Ocio EM, Paiva B, et al. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica 2012;97:1110–1114.
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999;94: 3576–3582.
   PubMed Web of Science ®Google Scholar
• Guikema JE, Vellenga E, Bakkus MH, et al. Myeloma clonotypic B-cells are hampered in their ability to undergo B-cell differentiation in vitro. Br J Haematol 2002;119:54–61.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Jensen L, Johnsen HE. The clonal hierarchy in multiple myeloma. Acta Oncol 2000;39:765–770.
   PubMed Web of Science ®Google Scholar
• Pfeifer S, Perez-Andres M, Ludwig H, et al. Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis. Leukemia 2011;25: 1213–1216.
   PubMed Web of Science ®Google Scholar
• Van Valckenborgh E, Matsui W, Agarwal P, et al. Tumor-initiating capacity of CD138- and CD138 + tumor cells in the 5T33 multiple myeloma model. Leukemia 2012;26:1436–1439.
   PubMed Web of Science ®Google Scholar
• Christensen JH, Jensen PV, Kristensen IB, et al. Characterization of potential CD138 negative myeloma “stem cells”. Haematologica 2012;97:e18–e20.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Honore L, Johnsen HE. Identification and characterization of malignant cells using RT-PCR on single flow sorted cells. Med Oncol 1998;15:96–102.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Haaber J, Dahl IM, et al. Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. Haematologica 2010; 95:1730–1737.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Jensen L, Johnsen HE. The CD19 compartment in myeloma includes a population of clonal cells persistent after high-dose treatment. Leuk Lymphoma 2002;43:1075–1077.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Jensen L, Honoré L, et al. Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma. Blood 2000;96: 4357–4359.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Johnsen HE. Controversies surrounding the circulating clonotypic B lymphocytes in multiple myeloma. Response to: Clonotypic B cells in the peripheral blood of patients with multiple myeloma. Blood 2001;97:2913–2914.
   Google Scholar
• Rasmussen T, Jensen L, Johnsen HE. Levels of circulating CD19 + cells in patients with multiple myeloma. Blood 2000; 95:4020–4021.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Jensen L, Honoré L, et al. Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-time RT-PCR assays. Br J Haematol 1999;107: 818–824.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Kastrup J, Knudsen LM, et al. High numbers of clonal CD19 + cells in the peripheral blood of a patient with multiple myeloma. Br J Haematol 1999;105:265–267.
   PubMed Web of Science ®Google Scholar
• Irish JM, Myklebust JH, Alizadeh AA, et al. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci USA 2010;107:12747–12754.
   PubMed Web of Science ®Google Scholar
• Irish JM, Czerwinski DK, Nolan GP, et al. Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol 2006;177:1581–1589.
   PubMed Web of Science ®Google Scholar
• Irish JM, Czerwinski DK, Nolan GP, et al. Altered B-cell receptor signaling kinetics distinguishes human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 2006; 108:3135–3142.
   PubMed Web of Science ®Google Scholar